Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224711 · ClinicalTrials.gov registry record · Phase 4
The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 2,290
- Enrollment target
NCT07224711: Clinical Trial Phase 4 study, sponsored by Vanderbilt University Medical Center.
NCT07224711 is a Phase 4 study that has not yet begun recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 2,290 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (342% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224711, a Phase 4 study, has not yet begun recruiting, sponsored by Vanderbilt University Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,290 participants
- Enrollment target
Study Summary
The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aims to answer are: The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS). The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).
Primary Outcome
The difference of CARLOS between the placebo and experimental groups in days. The Case Mix Index-Adjusted Resource Length of Stay is a hospital quality metric that standardizes average length of stay (LOS) to account for the complexity and severity of a hospital's patient population, represented by its Case Mix Index (CMI). A higher CMI indicates a more resource-intensive patient group, while a lower CMI reflects a simpler, less costly case mix.
Interventions
- DRUG Sodium Chloride 0.9%
- DRUG Lidocaine HCl 0.8% in D5W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,290 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 4 |
What is known before NCT07224711 opens enrollment
NCT07224711 is an interventional study that assigns participants to a tested intervention. Its 2,290 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (342% higher).
The record links to 0 conditions, and to 2 interventions - of which Sodium Chloride 0.9% is the first listed.
NCT07224711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07224711 about?
NCT07224711 is a clinical study titled "The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery". The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aim...
What is the current status of trial NCT07224711?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 2,290 participants. The study started on 2026-07-01. Estimated completion is 2028-05-30.
What interventions are being tested in trial NCT07224711?
The interventions under investigation include: Sodium Chloride 0.9% (DRUG), Lidocaine HCl 0.8% in D5W (DRUG).
Who is sponsoring clinical trial NCT07224711?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07224711's enrollment target sits among peer trials
2,290 31st of 2000 higher than 1,970 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05530343 · 2,298 participants · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- NCT05732623 · 2,300 participants
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI